NO20071322L - Humane veksthormonkonjugater av glyserolforgrenet polyetylenglycol, fremgangsmate for dens fremstilling og fremgangsmate for anvendelse derav - Google Patents
Humane veksthormonkonjugater av glyserolforgrenet polyetylenglycol, fremgangsmate for dens fremstilling og fremgangsmate for anvendelse deravInfo
- Publication number
- NO20071322L NO20071322L NO20071322A NO20071322A NO20071322L NO 20071322 L NO20071322 L NO 20071322L NO 20071322 A NO20071322 A NO 20071322A NO 20071322 A NO20071322 A NO 20071322A NO 20071322 L NO20071322 L NO 20071322L
- Authority
- NO
- Norway
- Prior art keywords
- growth hormone
- human growth
- preparation
- polyethylene glycol
- branched polyethylene
- Prior art date
Links
- 102000002265 Human Growth Hormone Human genes 0.000 title abstract 6
- 108010000521 Human Growth Hormone Proteins 0.000 title abstract 6
- 239000000854 Human Growth Hormone Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 title 3
- 239000002202 Polyethylene glycol Substances 0.000 title 1
- 229920001223 polyethylene glycol Polymers 0.000 title 1
- 230000006320 pegylation Effects 0.000 abstract 2
- 206010012559 Developmental delay Diseases 0.000 abstract 1
- 208000037824 growth disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60594504P | 2004-08-31 | 2004-08-31 | |
PCT/IB2005/002939 WO2006024953A2 (fr) | 2004-08-31 | 2005-08-25 | Conjugues d'hormone de croissance humaine polyethylene glycol ramifie, processus de preparation et procedes d'utilisation de ces conjugues |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20071322L true NO20071322L (no) | 2007-05-29 |
Family
ID=35708806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20071322A NO20071322L (no) | 2004-08-31 | 2007-03-09 | Humane veksthormonkonjugater av glyserolforgrenet polyetylenglycol, fremgangsmate for dens fremstilling og fremgangsmate for anvendelse derav |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1789092A2 (fr) |
JP (1) | JP2008511610A (fr) |
KR (1) | KR20070042567A (fr) |
CN (1) | CN101010105A (fr) |
AP (1) | AP2007003919A0 (fr) |
AR (1) | AR050851A1 (fr) |
AU (1) | AU2005278903A1 (fr) |
BR (1) | BRPI0515118A (fr) |
CA (1) | CA2577999A1 (fr) |
CR (1) | CR8942A (fr) |
EA (1) | EA200700380A1 (fr) |
EC (1) | ECSP077281A (fr) |
GT (1) | GT200500235A (fr) |
IL (1) | IL181085A0 (fr) |
MA (1) | MA28908B1 (fr) |
MX (1) | MX2007002441A (fr) |
NL (1) | NL1029828C2 (fr) |
NO (1) | NO20071322L (fr) |
PE (1) | PE20060654A1 (fr) |
TN (1) | TNSN07078A1 (fr) |
TW (1) | TW200621291A (fr) |
UY (1) | UY29088A1 (fr) |
WO (1) | WO2006024953A2 (fr) |
ZA (1) | ZA200701802B (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69838552T2 (de) | 1997-07-14 | 2008-05-21 | Bolder Biotechnology, Inc., Louisville | Derivate des wachstumshormons und verwandte proteine |
US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
JP2002534119A (ja) | 1999-01-14 | 2002-10-15 | ボルダー バイオテクノロジー, インコーポレイテッド | 自由システイン残基を有するタンパク質の生産方法 |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
EP1834963A1 (fr) * | 2006-03-13 | 2007-09-19 | Siegfried Ltd. | Conjugues de proteines et de dipolymeres et leurs procedes de preparation |
US20090117077A1 (en) * | 2006-05-12 | 2009-05-07 | Dong-A Pharm. Co., Ltd. | Polyethylene glycol-interferon alpha conjugate |
JP2008069073A (ja) * | 2006-09-12 | 2008-03-27 | Yokohama Tlo Co Ltd | ラクトフェリン複合体及びその製造方法 |
KR101079993B1 (ko) * | 2006-11-17 | 2011-11-04 | 동아제약주식회사 | 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체 |
CL2008002399A1 (es) | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c. |
WO2010011096A2 (fr) * | 2008-07-23 | 2010-01-28 | Hanmi Pharmaceutical Co., Ltd. | Complexe de polypeptide comprenant un polymère non-peptidylique ayant trois extrémités fonctionnelles |
MY156568A (en) | 2008-07-31 | 2016-03-15 | Pharmaessentia Corp | Peptide-polymer conjugates |
SI2340271T1 (sl) * | 2008-10-10 | 2019-08-30 | Polyactiva Pty Ltd. | Konjugati polimer-bioaktivnega sredstva |
US8535655B2 (en) | 2008-10-10 | 2013-09-17 | Polyactiva Pty Ltd. | Biodegradable polymer—bioactive moiety conjugates |
CA2739078C (fr) * | 2008-10-10 | 2017-01-03 | The Bionic Ear Institute | Conjugues polymere biodegradable - fractions bioactives |
US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
DK2393828T3 (en) | 2009-02-03 | 2017-01-23 | Amunix Operating Inc | Extended recombinant polypeptides and compositions comprising same |
US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
CN102612376A (zh) | 2009-08-06 | 2012-07-25 | 诺沃-诺迪斯克保健股份有限公司 | 具有延长的体内功效的生长激素 |
CN101831067A (zh) * | 2010-05-31 | 2010-09-15 | 王二新 | 聚乙二醇脂类缀合物及其在制备药物中的应用 |
EP2446898A1 (fr) | 2010-09-30 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Utilisation de l'hormone de croissance pour améliorer la réponse immunitaire chez des patients immunodéprimés |
CN102367290B (zh) * | 2011-04-26 | 2013-05-08 | 厦门赛诺邦格生物科技有限公司 | 链官能化的多级支化聚乙二醇及其合成方法 |
WO2014110867A1 (fr) * | 2013-01-17 | 2014-07-24 | 厦门赛诺邦格生物科技有限公司 | Polyéthylèneglycol ramifié monofonctionnel et substance de type biologique modifiée par celui-ci |
CN104877127B (zh) | 2015-06-23 | 2017-11-10 | 厦门赛诺邦格生物科技股份有限公司 | 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质 |
EA037151B1 (ru) | 2014-11-06 | 2021-02-11 | Фармаэссентия Корпорейшн | Способ лечения с использованием пегилированного интерферона |
CN111727063A (zh) * | 2017-12-29 | 2020-09-29 | 豪夫迈·罗氏有限公司 | 用于提供聚乙二醇化蛋白质组合物的方法 |
JP7137625B2 (ja) * | 2017-12-29 | 2022-09-14 | エフ.ホフマン-ラ ロシュ アーゲー | Peg化タンパク質組成物を提供するための方法 |
ES2905105T3 (es) | 2017-12-29 | 2022-04-07 | Hoffmann La Roche | Procedimiento para proporcionar una composición de proteína PEGilada |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2147192A (en) * | 1991-06-28 | 1993-01-25 | Genentech Inc. | Method of stimulating immune response using growth hormone |
JP3092531B2 (ja) * | 1996-11-05 | 2000-09-25 | 日本油脂株式会社 | コハク酸イミジル基置換ポリオキシアルキレン誘導体の製造方法 |
DE69838552T2 (de) * | 1997-07-14 | 2008-05-21 | Bolder Biotechnology, Inc., Louisville | Derivate des wachstumshormons und verwandte proteine |
JP3921781B2 (ja) * | 1998-02-12 | 2007-05-30 | 日本油脂株式会社 | カルボキシル基含有ポリオキシアルキレン化合物 |
JP2002534119A (ja) * | 1999-01-14 | 2002-10-15 | ボルダー バイオテクノロジー, インコーポレイテッド | 自由システイン残基を有するタンパク質の生産方法 |
JP2005525302A (ja) * | 2001-11-20 | 2005-08-25 | ファルマシア・コーポレーション | 化学的に修飾されたヒト成長ホルモンコンジュゲート |
BR0314172A (pt) * | 2002-09-09 | 2005-07-26 | Nektar Therapeutics Al Corp | Polìmero solúvel em água, composição, forma de hidrato ou acetal, composto,composição, usos do composto e do conjugado, e, processo para preparar o conjugado |
JP4412461B2 (ja) * | 2002-11-20 | 2010-02-10 | 日油株式会社 | 修飾された生体関連物質、その製造方法および中間体 |
MXPA05007165A (es) * | 2002-12-31 | 2005-09-21 | Nektar Therapeutics Al Corp | Reactivos polimericos que comprnden una cetona o un grupo funcional relacionado. |
EA011351B1 (ru) * | 2003-05-23 | 2009-02-27 | Нектар Терапеутикс Ал, Корпорейшн | Полимерные реагенты, способы их получения, а также содержащие их конъюгаты и фармацевтические препараты |
-
2005
- 2005-08-25 WO PCT/IB2005/002939 patent/WO2006024953A2/fr active Application Filing
- 2005-08-25 CN CNA2005800291171A patent/CN101010105A/zh active Pending
- 2005-08-25 MX MX2007002441A patent/MX2007002441A/es unknown
- 2005-08-25 JP JP2007529040A patent/JP2008511610A/ja active Pending
- 2005-08-25 AP AP2007003919A patent/AP2007003919A0/xx unknown
- 2005-08-25 CA CA002577999A patent/CA2577999A1/fr not_active Abandoned
- 2005-08-25 EA EA200700380A patent/EA200700380A1/ru unknown
- 2005-08-25 AU AU2005278903A patent/AU2005278903A1/en not_active Abandoned
- 2005-08-25 KR KR1020077004912A patent/KR20070042567A/ko not_active Application Discontinuation
- 2005-08-25 BR BRPI0515118-0A patent/BRPI0515118A/pt not_active IP Right Cessation
- 2005-08-25 EP EP05784225A patent/EP1789092A2/fr not_active Withdrawn
- 2005-08-26 PE PE2005000991A patent/PE20060654A1/es not_active Application Discontinuation
- 2005-08-29 UY UY29088A patent/UY29088A1/es not_active Application Discontinuation
- 2005-08-29 AR ARP050103612A patent/AR050851A1/es unknown
- 2005-08-30 NL NL1029828A patent/NL1029828C2/nl not_active IP Right Cessation
- 2005-08-30 GT GT200500235A patent/GT200500235A/es unknown
- 2005-08-30 TW TW094129583A patent/TW200621291A/zh unknown
-
2007
- 2007-01-31 IL IL181085A patent/IL181085A0/en unknown
- 2007-02-26 CR CR8942A patent/CR8942A/es not_active Application Discontinuation
- 2007-02-27 TN TNP2007000078A patent/TNSN07078A1/fr unknown
- 2007-02-27 EC EC2007007281A patent/ECSP077281A/es unknown
- 2007-02-28 ZA ZA200701802A patent/ZA200701802B/xx unknown
- 2007-02-28 MA MA29724A patent/MA28908B1/fr unknown
- 2007-03-09 NO NO20071322A patent/NO20071322L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ECSP077281A (es) | 2007-03-29 |
EA200700380A1 (ru) | 2007-10-26 |
WO2006024953A3 (fr) | 2007-01-18 |
NL1029828A1 (nl) | 2006-03-01 |
PE20060654A1 (es) | 2006-08-12 |
MX2007002441A (es) | 2007-05-04 |
TW200621291A (en) | 2006-07-01 |
CN101010105A (zh) | 2007-08-01 |
NL1029828C2 (nl) | 2006-10-20 |
BRPI0515118A (pt) | 2008-07-01 |
UY29088A1 (es) | 2006-03-31 |
CR8942A (es) | 2007-08-16 |
IL181085A0 (en) | 2007-07-04 |
AP2007003919A0 (en) | 2007-02-28 |
MA28908B1 (fr) | 2007-10-01 |
AU2005278903A1 (en) | 2006-03-09 |
ZA200701802B (en) | 2008-08-27 |
KR20070042567A (ko) | 2007-04-23 |
WO2006024953A2 (fr) | 2006-03-09 |
EP1789092A2 (fr) | 2007-05-30 |
GT200500235A (es) | 2006-03-21 |
CA2577999A1 (fr) | 2006-03-09 |
AR050851A1 (es) | 2006-11-29 |
JP2008511610A (ja) | 2008-04-17 |
TNSN07078A1 (fr) | 2008-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20071322L (no) | Humane veksthormonkonjugater av glyserolforgrenet polyetylenglycol, fremgangsmate for dens fremstilling og fremgangsmate for anvendelse derav | |
CY1119309T1 (el) | Συνδυασμενη χρηση toy (+)-1,4-διϋδρο-7-[(3s,4s)-3-meθoξy-4-(μεθυλαμινο)-1-πυρρολιδινυλ]-4-οξο-1(2-θειαζολυλ)-1,8-ναφθυριδιν-3-καρβοξυλικου οξεος και της κυταραβινης (ara-c) για την αγωγη της λευχαιμιας | |
WO2006058539A3 (fr) | Ligands du recepteur 1a de secretagogue de l'hormone de croissance | |
BRPI0418745A (pt) | anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente | |
ATE463239T1 (de) | Verfahren zur herstellung von sterilen suspensionen oder lyophilisaten schwerlöslicher basischer peptidkomplexe, diese enthaltende pharmazeutische formulierungen sowie ihre verwendung als arzneimittel | |
NO20063926L (no) | N-terminale monopegylerte humane veksthormonkonjugater, fremgangsmater for fremstilling og anvendelse av disse | |
WO2006004959A3 (fr) | Peg-interferon alpha-1b | |
DK1781256T3 (da) | Phospholipid-gel-sammensætning til lægemiddelafgivelse og fremgangsmåder til behandling af sygdomme ved hjælp af samme | |
WO2006138608A3 (fr) | Compositions pharmaceutiques et leur utilisation | |
RU2008145084A (ru) | Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo | |
NO20060924L (no) | Sammensetning av en VEGF- antagonist og en anti-proliferativ agens | |
YU75903A (sh) | Tiohidantoini i njihovo korišćenje u lečenju dijabetisa | |
CY1112257T1 (el) | Μεθοδοι αγωγης των φλεγμονωδων παθησεων χρησιμοποιωντας ειδικους παραγοντες δεσμευσης της ανθρωπινης αγγειοποιητινης-2 | |
ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
CY1112376T1 (el) | Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2 | |
WO2008082507A3 (fr) | Compositions pharmaceutiques et procédé de traitement d'une inflammation dans le bétail et autres animaux | |
DK2229440T3 (da) | Rekombinante elastase-proteiner og fremgangsmåder til fremstilling og anvendelse deraf | |
DE50211137D1 (de) | Seitenkettenhalogenierte aminodicarbonsaurederivate als arzneimittel zur behandlung von herz-kreislauf-erkrankungen | |
WO2007050121A3 (fr) | Hemoglobine pegylee a site specifique, procede de preparation afferent et utilisations associees | |
WO2003093419A3 (fr) | Prevention de lymphoedeme secondaire avec un adn de vegf-d | |
NO20024673D0 (no) | Farmasöytisk sammensetning med kontrollert frigivning for oral anvendelse inneholdende midodrin og/eller desglymidodrin | |
DK1596879T3 (da) | Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis | |
DK1537132T3 (da) | Salt af mortin-6-glucuronid | |
ATE545421T1 (de) | Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat | |
WO2005048993A3 (fr) | Minimisation de l'oxydation des medicaments dans des formulations pharmaceutiques renfermant des excipients irradies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |